Background Alzheimer’s disease (AD) and vascular dementia (VaD) have become significant global health challenges. Recent research evidence indicates a close comorbidity between AD and cerebral small vessel disease. The C677T (rs1801133, also known as c.665C > T) and A1298C (rs1801131) polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene have been associated with both conditions, though conclusions vary across studies. Methods We conducted a systematic search of PubMed, Embase, Web of Science and the Cochrane Library, covering the period from the inception of these databases to January 2026. Studies reporting the distribution of MTHFR C677T and/or A1298C genotypes were included. A fixed-effects model was used to calculate the pooled odds ratio (OR) and its 95% confidence interval (CI). Sensitivity analyses using random-effects models were also performed to test the robustness of the findings. Subgroup analyses were performed according to type of dementia and ethnicity. Results A total of 26 C677T studies and 8 A1298C studies were included. In the allele contrast model (T vs. C), C677T was significantly associated with dementia (OR = 1.40, 95% CI 1.05–1.87, p = 0.021) and AD (OR = 1.40, 95% CI 1.01–1.93, p = 0.043), but no statistically significant association was observed for VaD (OR = 1.42, 95% CI 0.76–2.66, p = 0.266). C677T showed no significant association under homozygous, heterozygous, dominant, or recessive inheritance models. No significant heterogeneity in association was observed across racial subgroups. A1298C showed no significant association with dementia under any genetic model. Conclusion This meta-analysis showed that the MTHFR C677T T allele is associated with the risk of AD in an allele-dependent model, with a similar but non-significant trend for VaD. The A1298C polymorphism shows no association with either type of dementia. These findings suggest that C677T genotyping may aid AD risk stratification in research, but it requires prospective validation and gene-environment studies before clinical use.
Yu-Yao He, Yandan Shi, Jin-Hua Hu et al.· Frontiers in Aging Neuroscie...· 0 citations
OBJECTIVE
Di-(2-ethylhexyl) phthalate (DEHP) is a widespread environmental obesogen; however, its immune-proinflammatory mechanisms in the progression of metabolic dysfunction-associated steatohepatitis (MASH) remain incompletely elucidated. This study aims to comprehensively characterize the core targets and molecular mechanisms by which DEHP disrupts the hepatic microenvironment and drives disease progression through multi-omics integration and experimental analysis.
METHODS
Real-world clinical transcriptomic cohorts were integrated and combined with LASSO and SVM-RFE machine learning algorithms to screen for core pathogenic genes intersecting MASH and DEHP exposure. Single-cell RNA sequencing (scRNA-seq) and virtual knockout (scTenifoldKnk) technologies were utilized to decipher the cell-type-specific expression of target genes and their downstream regulatory networks. The binding mode between the small molecule and the protein was evaluated using CB-Dock2. Furthermore, siRNA interference, Western blotting, real-time quantitative PCR, and Transwell assays were comprehensively applied in HepG2 and THP-1 cell models to systematically verify the biological functions of the "DEHP-target gene-chemokine" regulatory cascade.
RESULTS
Machine learning algorithms accurately identified the transcription factor FOS as the core hub gene for DEHP-mediated MASH regulation, which showed promising diagnostic potential. Following resampling validation in a small independent cohort, FOS yielded an adjusted AUC of 0.964, though future validation in larger populations is warranted. Single-cell mapping revealed a significant downregulation of FOS expression within the MASH hepatic immune microenvironment, particularly in monocyte and NK cell subpopulations; systematic virtual knockout simulation predicted that FOS suppression potentially leads to substantial activation of chemokine signaling pathways. In vitro cellular experiments corroborated that DEHP induces hepatic lipid accumulation and biochemical injury in a dose-dependent manner, while targeted FOS knockdown further exacerbates this lipotoxic phenotype. Molecular docking studies suggested that DEHP potentially interacts with the binding pocket of the FOS protein through a multiple-hydrogen-bond network, thereby suppressing its transcription and translation. The suppression of FOS expression abolishes its physiological negative regulation of downstream chemokines, resulting in the high-level release of CCL3 and CCL4, which subsequently drives the transmembrane chemotaxis and infiltration of peripheral monocytes into the liver.
CONCLUSIONS
This study suggests a potential mechanism by which DEHP exposure may promote monocyte infiltration and exacerbate MASH pathogenesis, potentially by interacting with and inhibiting the core regulatory protein FOS, thereby relieving its suppressive effect on CCL3/CCL4. These findings deepen our understanding of the "multiple-hit" mechanism by which environmental endocrine disruptors participate in liver diseases, highlighting FOS as a potential biomarker for environment-related metabolic diseases that warrants further thorough in vivo validation before considering it as a clinical intervention target.
Chaojie Wang, Zhihao Zhang, Yuqing Huang et al.· Ecotoxicology and Environmen...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
